Literature DB >> 12559780

Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization.

Dan Frenkel1, Ilse Dewachter, Fred Van Leuven, Beka Solomon.   

Abstract

Antibodies to the epitope EFRH, representing residues 3-6 within the beta-amyloid (Abeta) sequence, were previously shown to affect the solubility and disaggregation of Abeta fibrils in vitro. Here, we describe a novel method of immunization, using as antigen the EFRH peptide displayed on the surface of the filamentous phage. The EFRH phage evoked effective auto-immune antibodies in amyloid precursor protein [V717I] (APP[V717I]) transgenic mice that recapitulate the amyloid plaques and vascular pathology of Alzheimer's disease (AD). The immunization provoked a considerable reduction in the number of Abeta amyloid plaques in the brain of the transgenic mice and may serve as the basis for anti-Abeta vaccine. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12559780     DOI： 10.1016/s0264-410x(02)00609-6

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  23 in total

1.  EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials.

Authors:  Vered Lavie; Maria Becker; Rachel Cohen-Kupiec; Iftach Yacoby; Rela Koppel; Manuela Wedenig; Birgit Hutter-Paier; Beka Solomon
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 2.  Murine models of Alzheimer's disease and their use in developing immunotherapies.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Biochim Biophys Acta       Date:  2010-05-13

3.  Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer's disease.

Authors:  Rinaldo Zurbriggen; Mario Amacker; Andreas R Kammer; Nicole Westerfeld; Peter Borghgraef; Fred Van Leuven; Ingrid Van der Auwera; Stefaan Wera
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

4.  Stimulation of endogenous neurogenesis by anti-EFRH immunization in a transgenic mouse model of Alzheimer's disease.

Authors:  Maria Becker; Vered Lavie; Beka Solomon
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-22       Impact factor: 11.205

Review 5.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

Review 6.  Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

Authors:  Thomas Wisniewski; Allal Boutajangout
Journal:  Brain Struct Funct       Date:  2009-12-10       Impact factor: 3.270

7.  Expression of a 28-kilodalton glutathione S-transferase antigen of Schistosoma mansoni on the surface of filamentous phages and evaluation of its vaccine potential.

Authors:  Kakuturu V N Rao; Yi-Xun He; Ramaswamy Kalyanasundaram
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

8.  Molecular basis for passive immunotherapy of Alzheimer's disease.

Authors:  Anna S Gardberg; Lezlee T Dice; Susan Ou; Rebecca L Rich; Elizabeth Helmbrecht; Jan Ko; Ronald Wetzel; David G Myszka; Paul H Patterson; Chris Dealwis
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-25       Impact factor: 11.205

Review 9.  Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials.

Authors:  Donna M Wilcock; Carol A Colton
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

Review 10.  Inflammaging as a prodrome to Alzheimer's disease.

Authors:  Brian Giunta; Francisco Fernandez; William V Nikolic; Demian Obregon; Elona Rrapo; Terrence Town; Jun Tan
Journal:  J Neuroinflammation       Date:  2008-11-11       Impact factor: 8.322
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.